Apellis Pharmaceuticals, Inc. — Director's Dealing 2023

Jan 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2023-01-23

Reporting Person: Lewis Karen (Chief People Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-23	Common Stock	S	2955	$51.58	Disposed	37709	Direct

Footnotes

F1: Sale originated from established 10b5-1 trading plan.